Distinct transcriptional changes in non-small cell lung cancer patients associated with multi-antigenic RNActive® CV9201 immunotherapy

We recently completed a phase I/IIa trial of RNActive® CV9201, a novel mRNA-based therapeutic vaccine targeting five tumor-associated antigens in non-small cell lung cancer (NSCLC) patients. The aim of the study presented here was to comprehensively analyze changes in peripheral blood during the vac...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Henoch S., Koch, Sven D., Scheel, Birgit, Gnad-Vogt, Ulrike, Schröder, Andreas, Kallen, Karl-Josef, Wiegand, Volker, Backert, Linus, Kohlbacher, Oliver, Hoerr, Ingmar, Fotin-Mleczek, Mariola, Billingsley, James M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5214806/
https://www.ncbi.nlm.nih.gov/pubmed/28123889
http://dx.doi.org/10.1080/2162402X.2016.1249560

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5214806/
https://www.ncbi.nlm.nih.gov/pubmed/28123889
http://dx.doi.org/10.1080/2162402X.2016.1249560

Ejemplares similares